We Claim:

1. An immunogenic composition comprising:

   (1) a multivalent polysaccharide-protein conjugate mixture consisting of capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F of *Streptococcus pneumoniae* conjugated to a carrier protein; and

   (2) a pharmaceutically acceptable carrier.

2. The immunogenic composition of claim 1, wherein the carrier protein is CRM\textsubscript{197}.

3. The immunogenic composition of claim 1, further comprising an adjuvant.

4. The immunogenic composition claim 3, wherein the adjuvant is an aluminum-based adjuvant.

5. The immunogenic composition of claim 4, wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide.

6. The immunogenic composition of claim 5, wherein the adjuvant is aluminum phosphate.

7. The immunogenic composition of claim 1 formulated as single 0.5 mL dose containing 2 μg of each saccharide, except for 6B at 4 μg; about 32 μg CRM\textsubscript{197} carrier protein; 0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; 150 mM sodium chloride and 20 mM L-histidine buffer.

7–8. A method of inducing an immune response to a *Streptococcus pneumoniae* capsular polysaccharide, comprising administering to a human an immunologically effective amount of the immunogenic composition of claim 1.

8–9. The method of claim 7–8, wherein the immunogenic composition administered is a single 0.5 mL dose formulated to contain: 2 μg of each saccharide, except for 6B at 4 μg; about 32 μg CRM\textsubscript{197} carrier protein; 0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; 150 mM sodium chloride and 20 mM L-histidine buffer.